South Africa Ophthalmic Drugs Market Size & Outlook
Related Markets
South Africa ophthalmic drugs market highlights
- The South Africa ophthalmic drugs market generated a revenue of USD 227.3 million in 2025 and is expected to reach USD 447.9 million by 2033.
- The South Africa market is expected to grow at a CAGR of 8.8% from 2026 to 2033.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2025.
- Anti-VEGF agents is the most lucrative drug class segment registering the fastest growth during the forecast period.
Ophthalmic drugs market data book summary
| Market revenue in 2025 | USD 227.3 million |
| Market revenue in 2033 | USD 447.9 million |
| Growth rate | 8.8% (CAGR from 2026 to 2033) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Anti-VEGF agents |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-VEGF agents, Anti-glaucoma, Anti-inflammatory, Anti-Allergy |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.5% of the global ophthalmic drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, South Africa ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2033.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 447.9 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Nicox SA Share from reverse split | View profile | 29 | Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, France, 06410 | https://www.nicox.com |
| Coherus BioSciences Inc | View profile | 306 | 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 | https://www.coherus.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | http://gene.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Regeneron Pharmaceuticals Inc | View profile | 13450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | https://www.regeneron.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Alcon Inc | View profile | 25315 | Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 | https://www.alcon.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
South Africa ophthalmic drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 37.44% in 2025. Horizon Databook has segmented the South Africa ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy covering the revenue growth of each sub-segment from 2021 to 2033.
The South African market is expected to witness significant growth due to improved infrastructure and healthcare-related regulations. The South African government commemorated the 20th of September to the 17th of October as the eye care awareness month to raise awareness about the importance of eye health.
Moreover, in September 2022, the South African Optometric Association planned to increase awareness about preventable blindness and the importance of routine eye examinations. Such initiatives are expected to boost the growth of the ophthalmic drugs market over the forecast period.
Furthermore, aging generates structural and physiological changes that predispose humans to visual morbidity (such as presbyopia, AMD, cataract, and glaucoma), which contributes to market growth. According to the United Nations Population Fund's 2022 statistics, a major proportion of the live population of South Africa is aged 15-64, accounting for 66% in 2022.
Reasons to subscribe to South Africa ophthalmic drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa ophthalmic drugs market databook
-
Our clientele includes a mix of ophthalmic drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into South Africa ophthalmic drugs market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa Anti-inflammatory - Ophthalmic Drugs Market, 2025 - 2033 (US$M)
South Africa Ophthalmic Drugs Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
